Therapy News and Research

RSS

BioDiem signs agreement with RMIT to create new non-influenza vaccines

Australian infectious disease therapy and vaccine development company BioDiem Ltd (ASX: BDM) today announced that BioDiem has signed an agreement with The Royal Melbourne Institute of Technology (RMIT) regarding a research program that will investigate the use of BioDiem’s live attenuated influenza virus (LAIV) to create new non-influenza vaccines. Developing the potential of the LAIV technology for new indications is an important part of BioDiem’s strategy, and this research is part of the work towards that goal.

19 Jul 2012

Weighing up the gains for smokers who quit

People seem to gain more weight after giving up smoking than has previously been estimated, report researchers.

19 Jul 2012

Primcogent Solutions introduces low level laser therapy for onychomycosis

Primcogent Solutions - supplier of the revolutionary ZERONA non-invasive body contouring technology in North America and Western Europe - has announced the launch of Lunula Laser, a clinically proven, low level laser therapy for onychomycosis, for distribution exclusively in Europe.

19 Jul 2012

UNMC's ART injectables can successfully treat HIV infection

This has been a good week for breakthroughs in HIV/AIDS. Earlier this week, the Food and Drug Administration approved a daily pill, Truvada, which reduces the risk of HIV infection. Today, a University of Nebraska Medical Center research team's progress toward developing weekly or twice-monthly injectable antiretroviral therapy (ART) nanomedicines for patients with human immunodeficiency virus (HIV) infection will be highlighted as the cover story in the Journal of Infectious Diseases.

19 Jul 2012

Bryologs more potent than prostratin in treating HIV

Thanks to antiretrovirals, an AIDS diagnosis hasn't been a death sentence for nearly two decades. But highly active antiretroviral therapy, or HAART, is also not a cure.

19 Jul 2012

New research sheds light on pluripotency

New research at the Hebrew University of Jerusalem sheds light on pluripotency-the ability of embryonic stem cells to renew themselves indefinitely and to differentiate into all types of mature cells.

19 Jul 2012

Study confirms safety and feasibility of optical coherence tomography in carotid arteries

Our ability to see inside the arteries of vascular disease patients in stunning high resolution before and during stenting procedures can offer a wealth of valuable information. A new study of optical coherence tomography (OCT) confirms the safety and feasibility of this imaging technique in the carotid arteries.

19 Jul 2012

Inhibiting STAT3 might unleash an effective anti-lymphoma immune response

Researchers at Moffitt Cancer Center and colleagues have demonstrated that the inhibition of signal transducer and activator of transcription 3 (STAT3) in mouse models of mantle cell lymphoma (MCL), an aggressive and incurable subtype of B-cell non-Hodgkin lymphoma that becomes resistant to treatment, can harness the immune system to eradicate residual malignant cells responsible for disease relapse.

19 Jul 2012

Positive preliminary results from Feraheme phase III study on iron deficiency anemia

AMAG Pharmaceuticals, Inc. today reported preliminary results from the second phase III study from its global registrational program for Feraheme (ferumoxytol) in patients with iron deficiency anemia (IDA) regardless of the underlying cause.

19 Jul 2012

Book details minimum recommended guidelines for radiation oncology practices

The American Society for Radiation Oncology (ASTRO) is proud to announce the publication of Safety is No Accident: A Framework for Quality Radiation Oncology and Care, a comprehensive book detailing minimum recommended guidelines for radiation oncology practices.

19 Jul 2012

New procedure can shut down irregular heart rhythms

Researchers from UC San Diego, the University of California Los Angeles and Indiana University report having found, for the first time, that atrial fibrillation or irregular heart rhythms is caused by small electrical sources within the heart, in the form of electrical spinning tops ("rotors") or focal beats. Importantly, they found a way of detecting these key sources, then precisely targeting them for therapy that can shut them down in minutes with long lasting results.

19 Jul 2012

Roundup: Ore. issues new long-term care insurance claims rules; Fla. pushing ahead with prison care privatization

The Oregon Insurance Division receives about 100 complaints about long-term-care policies each year, mostly about delays or denials. But now the state's role is increasing, thanks to a law that went into effect this month. The Oregon law requires insurers to process long-term care claims within 30 days when they're not in dispute. It also allows outside review when an insurer decides a person isn't sufficiently disabled for long-term care.

19 Jul 2012

Angion Biomedica initiates BB3 Phase II trial in heart attack

Angion Biomedica Corp. announced today that the first patient was dosed in a Phase II multicenter clinical trial evaluating BB3 for the treatment of heart attack (acute myocardial infarction).

19 Jul 2012

Researchers identify new behavior for the human macrophage

Researchers at the Institute of Human Virology of the University of Maryland School of Medicine have identified a new behavior for the human macrophage that provides new explanations for several features of HIV biology, including how the virus persists within the body indefinitely, how quiescently infected CD4+ T-cells arise, and how the infection leads to depletion of CD4+ T-cells.

19 Jul 2012